FDA warned W.S. Badger over repeat manufacturing-quality failures in OTC drug products, including sunscreen process, cleaning, test-method, and OOS investigation problems.
What happened
FDA inspected The W.S. Badger Company's drug manufacturing facility in Gilsum, NH, from August 30 to September 14, 2021, and reviewed the company's September 28, 2021 response to FDA's inspection observations form (Form FDA 483). The agency found missing or inadequate process and cleaning validation, unvalidated release and stability test methods used by a third-party contract testing laboratory, and inadequate investigations of repeated out-of-specification viscosity and high water activity results, some with bioburden failures. FDA said these were repeat violations and that the company had failed to meet earlier validation commitments.
What FDA found
The company lacked adequate written production and process controls, including process validation and cleaning validation, while releasing multiple OTC sunscreen batches, some with out-of-specification results; FDA called it a repeat violation.
21 CFR 211.100(a)The company released OTC drugs using third-party test methods that were not validated for accuracy, specificity, and reproducibility, including a zinc oxide method validated for another customer's products; FDA called it a repeat violation.
21 CFR 211.165(e)The company failed to thoroughly investigate repeated out-of-specification viscosity and high water activity results and bioburden failures, and its corrective actions were ineffective; FDA called it a repeat violation.
21 CFR 211.192
What FDA wants
FDA asks the company to provide a detailed validation program and timelines, cleaning validation improvements, an independent assessment of all test methods and laboratory systems, and a retrospective review of OOS results with remediation plans. The company must respond in writing within 15 working days, and FDA strongly recommends a qualified CGMP consultant.
Who should pay attention
- other OTC sunscreen and topical drug manufacturers
- brands using third-party contract testing laboratories
- retailers and distributors of OTC drug products
This is a summary. Read the original letter on fda.gov.